Questionnaire

1. Which statement best explains why glycaemic control remains important in T2DM, even with cardiorenal-protective therapies?

2. Guidelines prioritise early SGLT-2 inhibitor and/or GLP-1 RA use, particularly in patients with:

3. The ‘legacy effect’ (metabolic memory) supports which principle?

4. In patients above target despite GLP-1 RA therapy, adding basal insulin is best described as:

5. What characteristics best describes IGla-300?

6. SGLT-2 inhibitors reduce heart failure hospitalisation:

7. Which is a common contributor to clinical inertia with insulin therapy?

8. Basal insulin is particularly effective for correcting:

9. In the article, day-to-day glucose variability refers to:

10. Which factor can contribute to variability in basal insulin action?

11. A key practical point about basal insulin pharmacology is that duration of action is:

12. Which option best reflects why lower variability is clinically useful?

13. Which of the following may increase hypoglycaemia risk with basal insulin therapy?

14. When individualising HbA1c targets in older adults with limited life expectancy, the article emphasises prioritising:

15. In older adults with limited life expectancy, very strict HbA1c targets always outweigh hypoglycaemia risk: